The FDA approved GSK's blood cancer drug, Blenrep, in combination with bortezomib and dexamethasone for multiple myeloma patients who have received at least two prior lines of therapy.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
US FDA approves GSK's blood cancer treatment
